Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Blood Pressure Control
ED-Delivered Education Plus mHealth Lowers Systolic BP — TOUCHED Trial Shows a Modest but Meaningful 4.9 mm Hg Reduction at 6 Months
Posted inCardiology Emergency Medicine news

ED-Delivered Education Plus mHealth Lowers Systolic BP — TOUCHED Trial Shows a Modest but Meaningful 4.9 mm Hg Reduction at 6 Months

Posted by MedXY By MedXY 12/05/2025
The TOUCHED randomized trial found that an ED-initiated education plus mHealth and pharmacist/APRN consultation reduced systolic blood pressure by 4.9 mm Hg at 6 months versus usual care in patients discharged with elevated BP.
Read More
Dissecting the Care Bundle: Mediation Analysis of Key Components Driving Improved Outcomes in INTERACT3 for Acute Intracerebral Hemorrhage
Posted inClinical Updates Neurology news Nursing & care Specialties

Dissecting the Care Bundle: Mediation Analysis of Key Components Driving Improved Outcomes in INTERACT3 for Acute Intracerebral Hemorrhage

Posted by MedXY By MedXY 09/22/2025
Mediation analysis of INTERACT3 reveals that systolic blood pressure and blood glucose control are primary drivers of functional recovery benefits in acute intracerebral hemorrhage care bundles.
Read More
Equally Effective Dual Therapy Combinations for Hypertension in Indian Patients: Insights from a Landmark Randomized Trial
Posted inCardiology Clinical Updates

Equally Effective Dual Therapy Combinations for Hypertension in Indian Patients: Insights from a Landmark Randomized Trial

Posted by MedXY By MedXY 09/19/2025
This multicenter randomized trial in India shows that three dual antihypertensive combinations—amlodipine-perindopril, perindopril-indapamide, and amlodipine-indapamide—are equally effective and well-tolerated for 24-hour blood pressure control in South Asian adults.
Read More
Amiloride vs Spironolactone for Resistant Hypertension: A New Alternative Backed by Randomized Trial Evidence
Posted inCardiology Clinical Updates news

Amiloride vs Spironolactone for Resistant Hypertension: A New Alternative Backed by Randomized Trial Evidence

Posted by MedXY By MedXY 09/19/2025
A recent randomized clinical trial demonstrates amiloride's noninferiority to spironolactone in lowering systolic blood pressure in resistant hypertension, offering a promising alternative therapy.
Read More
Baxdrostat: A Promising New Agent for Managing Uncontrolled and Resistant Hypertension
Posted inCardiology Specialties

Baxdrostat: A Promising New Agent for Managing Uncontrolled and Resistant Hypertension

Posted by MedXY By MedXY 09/11/2025
Baxdrostat, a novel aldosterone synthase inhibitor, significantly reduces systolic blood pressure in patients with uncontrolled or resistant hypertension, offering a new therapeutic option with a favorable safety profile.
Read More
Balancing Benefits and Harms of Intensive Blood Pressure Control Across Cardiovascular Risk Levels
Posted inCardiology Clinical Updates news Specialties

Balancing Benefits and Harms of Intensive Blood Pressure Control Across Cardiovascular Risk Levels

Posted by MedXY By MedXY 08/12/2025
Intensive blood pressure control reduces cardiovascular events across all risk levels, with greater absolute benefits in higher-risk patients despite increased adverse events, supporting tailored treatment based on cardiovascular risk.
Read More
  • NT-501 Encapsulated Cell Therapy Successfully Slows Photoreceptor Loss in Macular Telangiectasia Type 2: Results from Two Phase 3 Trials
  • Beyond the Golden Years: Young COPD and Early Lung Function Decline as Critical Drivers of Premature Mortality and Cardiovascular Risk
  • High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial
  • IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
  • Post-PCI Troponin Kinetics Reveal Hemorrhagic Transformation as a Critical Driver of In-Hospital Mortality in STEMI
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial SGLT2 inhibitors targeted therapy treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in